Activity of single agent oxaliplatin in recurrent ovarian cancer, previously treated with cisplatin or carboplatin
Medical Journal of Cairo University [The]. 2003; 71 (4): 805-808
en Inglés
| IMEMR
| ID: emr-63730
ABSTRACT
This study included 28 females with recurrent ovarian cancer previously treated with combination chemotherapy including cisplatin or carboplatin. The platinum free interval was >6 - <12 months in 11 patients and >12 months in 17 patients. Oxaliplatin was prescribed in a dose of 130 mg/m2 administered over 2 hours every 21 days with an average of 5 cycles/patient. An overall response was achieved in ten patients with a median time to tumor progression and overall survival of 11 and 17 months, respectively. A favorable response was observed in the platinum sensitive group [platinum free interval of >12 months] as well as those cases with non-bulky recurrent disease. Oxaliplatin administration was associated with an accepted level of drug related toxicity
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Recurrencia
/
Tasa de Supervivencia
/
Estudios de Seguimiento
/
Carboplatino
/
Cisplatino
/
Resultado del Tratamiento
/
Compuestos de Platino
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Med. J. Cairo Univ.
Año:
2003
Similares
MEDLINE
...
LILACS
LIS